1. Please check and comment entries here.
Table of Contents

    Topic review

    5-HT2B Receptor in Fibrosing ILD

    Subjects: Pathology
    View times: 21
    Submitted by: Anna Löfdahl

    Definition

    Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 conditions, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, ILD associated with autoimmune diseases and sarcoidosis may present a progressive fibrosing (PF) phenotype. Despite different aetiology and histopathological patterns, the PF-ILDs have similarities regarding disease mechanisms with self-sustaining fibrosis, which suggests that the diseases may share common pathogenetic pathways. Previous studies show an enhanced activation of serotonergic signaling in pulmonary fibrosis, and the serotonin (5-HT)2 receptors have been implicated to have important roles in observed profibrotic actions.

    1. Introduction

    The term interstitial lung disease (ILD) encompasses a large heterogeneous group of diffuse parenchymal lung disorders, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, ILD associated with autoimmune diseases, hypersensitivity pneumonitis and sarcoidosis may present a progressive fibrosing (PF) phenotype [1]. Despite known or unknown causes and radiological patterns, the PF-ILDs have similarities regarding disease mechanisms with self-sustaining fibrosis [2], suggesting common pathogenetic pathways. In this review, we will address the potential role of serotonin (5-HT) and the 5-HT2B receptor in three PF-ILDs: IPF, ILD associated with systemic sclerosis (SSc-ILD) and ILD associated with rheumatoid arthritis (RA-ILD).

    2. Idiopathic Pulmonary Fibrosis

    Idiopathic pulmonary fibrosis is defined as usual interstitial pneumonia (UIP) based on high-resolution computed tomography (HRCT) and/or histopathological pattern after exclusion of other known causes of ILD [3]. IPF is the most common PF-ILD, and in a systematic review a conservative estimate of the incidence was 3–9 cases per 100,000 per year for Europe and North America with lower reports for East Asia and South America [4]. IPF is more prevalent in the older population, rarely diagnosed before the age of 70, and is more widely represented in males [5]. IPF patients demonstrate large heterogeneity in their pulmonary manifestation of fibrosis, and it is generally not regarded as an inflammatory disease, despite previous attempts to treat the disease with corticosteroids. Nonetheless, patients with a rapid progress or experiencing an acute exacerbation have reported severe innate and adaptive inflammatory infiltrates where the extent of inflammation was correlated with yearly forced vital capacity (FVC) decline [6].

    It is now widely recognized that the aetiology of IPF is a gene-environment interaction involving a heterogeneous set of susceptibility genes such as TERT, SFTPC, TOLLIP and MUC5B [7]. Environmental factors that have been linked to the development of IPF in epidemiological studies include smoking, chronic viral infections and occupational exposures, such as agriculture and farming, livestock, wood dust, metal dust, stone dust and silica [8]. The clinical course of IPF is highly heterogeneous, but carries a poor prognosis with a mean survival of four years [9]. On a yearly basis 5–10% of IPF patients experience acute deteriorations in respiratory function, exacerbations, with a median survival of 3 to 4 months [10].

    3. Systemic Sclerosis

    Systemic sclerosis is an autoimmune disease characterized by vasculopathy of small vessels, immune dysregulation, chronic inflammation, and subsequent fibrosis of the skin and internal organs [11]. Skin fibrosis (scleroderma) is the distinguishing hallmark of SSc, and the extent of skin involvement and its rate of progression reflect the severity of visceral organ involvement. The reported prevalence of SSc varies between studies, but has been estimated to be 15–30 cases per 100,000 individuals worldwide [12], with a peak onset described at 55–69 years of age [13]. Although SSc, like other autoimmune diseases, is more common in women than in men, the male sex is a poor prognostic factor with more frequent and severe organ involvement [14].

    ILD is a common and early manifestation of SSc, and most patients who develop severe restrictive lung disease do so in the first five years following the onset of SSc symptoms [15]. SSc-ILD often has a severe course, and was the leading cause of death (17%) in a large observational study in SSc [16]. The estimated prevalence of ILD has been reported at up to 84% on HRCT [17], and it has been suggested that pulmonary function tests should not be used for screening of ILD in SSc due to a lower sensitivity than HRCT [18]. The most common ILD pattern in SSc patients is nonspecific interstitial pneumonia (NSIP), although UIP can also be seen in 25–40% of cases [19].

    Patients are grouped into limited cutaneous SSc (lcSSc), where the skin fibrosis is restricted to areas distal to the elbows and knees, and diffuse cutaneous SSc (dcSSc) with involvement also of the proximal extremities and trunk. The extent of skin involvement is a prognostic risk factor for ILD and patients with dcSSc have both a higher prevalence and mortality from ILD than those with lcSSc [20]. In addition, male sex, ethnicity and presence of anti-topoisomerase antibodies appear to be important determinants of ILD development.

    4. Rheumatoid Arthritis

    Rheumatoid arthritis is a systemic inflammatory autoimmune disorder estimated to affect 0.5–1% of the world’s population. Although the predominant clinical feature is inflammation of the synovial lining of joints, RA has numerous extra-articular manifestations, and lung disease is a major contributor to the extra-articular morbidity and mortality. There are strong indications that lungs are involved in early pathogenesis of RA by citrullination of proteins triggered by environmental exposure of, e.g., tobacco smoke. Development of anti-citrullinated protein antibodies (ACPAs) in genetically susceptible individuals [21] may initiate inflammatory responses and autoimmune reactivity. ILD is one of the most common comorbidities associated with RA, significantly aggravating the patient’s disease course, prognosis, and health-related quality of life [22]. The prevalence of RA-ILD has been reported to be as high as 76% in imaging studies, but clinically significant ILD occurs in less than 10%, albeit with increasing incidence [23].

    The histopathology of RA-ILD is heterogeneous showing a highly variable mix of both fibrotic and inflammatory changes. Contrary to ILD associated with other connective tissue diseases, the most prevalent pattern in RA-ILD is UIP followed by NSIP, which can be further broken down into inflammatory and fibrotic subtypes [24]. Compared to RA patients with a non-UIP pattern, those with UIP confer a poorer prognosis with survival rates that are in parallel to those seen in IPF. The RA-ILD patients with UIP have been reported to have more respiratory-related hospitalizations than other ILD subtypes [25].

    Risk factors for the development of RA-ILD have been identified in several studies and include older age, male sex, cigarette smoking, later onset RA, longer RA duration, RA disease activity, and elevated levels of rheumatoid factor or anti-ACPA [26].

    5. Current Therapeutic Strategies

    Treatment of PF-ILD has changed considerably during the last two decades. Corticosteroids were during many years widely used for the treatment of fibrotic lung diseases, but serious concerns have been raised due to increased mortality of IPF patients receiving prednisone, azathioprine and N-acetylcysteine in a clinical trial [27] and the risk for renal crisis in patients with SSc [28]. In patients with SSc and RA, the therapy for the underlying disease has formed the basis for treatment of the ILD component. In RA and SSc, immunosuppressive therapies including cyclophosphamide, azathioprine, and mycophenolate mofetil are widely used, and in SSc, haematopoietic stem cell transplantation has also been successful. The first targeted antifibrotic drug, pirfenidone, was introduced for the treatment of IPF in Japan 2008, and a couple of years later in the EU and the US. Another antifibrotic drug, nintedanib, was approved for treatment of IPF in the US 2014 and in the EU 2015. Since then, both drugs have been investigated in clinical studies enrolling a wide range of PF-ILDs, leading to approvals for use in SSc-ILD regarding nintedanib in both the US and in the EU, and for pirfenidone in the US. Nintedanib was further approved in 2020 in the EU for use in other chronic fibrosing ILDs with a progressive phenotype. Several antifibrotic drugs are currently investigated for IPF in clinical phase 2–3 trials, some of them also targeting a broader spectrum of PF-ILDs [29]. Today, there is no curative treatment available for ILDs where lung transplantation stands as the final therapeutic measure.

    6. The Serotonergic Pathways in Tissue Repair and Fibrosis

    Serotonin (5-hydroxytryptamine, 5-HT) is a multifunctional signaling molecule, mainly recognized for its role in the central nervous system (CNS), where it regulates several behavioral processes. Even now, over 70 years after its discovery, the functional role of 5-HT is still not fully clarified, with emerging studies showing new biological influences and disease associations. A mechanistic link between fibrosis and 5-HT was first reported in the 1960s for a condition called carcinoid syndrome which is caused by neuroendocrine carcinoid tumors that secrete vast quantities of 5-HT [30]. The syndrome was characterized by tissue fibrosis, particularly affecting cardiac valves but also impacting on other organs including lung and skin. More recently, agonistic activity on the 5-HT2B receptor has been implicated in causing fibrosis, which led to the recall of fenfluramine used in the treatment of obesity, as well as pergolide, a drug used to treat Parkinson’s disease [31][32].
    The 5-HT2B receptor agonistic activity of these drugs has been suggested to lead to myofibroblast activation in a transforming growth factor (TGF)-β1 dependent manner, resulting in fibrosis [33][34]. Besides the 5-HT2B receptor, the receptor subtypes 5-HT2A and 5-HT2C
    have also been suggested to be involved in fibrosis. 5-HT has been described to play a role in alveolar macrophage function through 5-HT2C receptors and thereby affect fibrosis development [35], while the 5-HT2A receptor has been shown to induce a TGF-β dependent
    fibrotic response in vivo [36]. Among the other classes of receptors, 5-HT7 was in a recent paper by Tawfik et al. suggested to mediate anti-inflammatory and anti-fibrotic effects in the bleomycin-induced lung fibrosis model in rats [37]. However, the cellular mechanisms
    underlying PF-ILDs are still under investigation where the activation of specific 5-HT receptors remains an overlooked target in pulmonary fibrotic disorders. To understand the pathophysiological impact of 5-HT and the different 5-HT receptors, it is important to take into account the cellular context and the diversity in expression profile of the 5-HT receptors in different conditions. It is clear that activation of the 5-HT2B receptor critically affects several profibrotic responses, whereby modulating its activity has been shown to attenuate fibrosis [38][39][40.

    This entry is adapted from 10.3390/ijms22010225

    References

    1. Cottin, V.; Hirani, N.A.; Hotchkin, D.L.; Nambiar, A.M.; Ogura, T.; Otaola, M.; Skowasch, D.; Park, J.S.; Poonyagariyagorn, H.K.; Wuyts, W.; et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018, 27, 180076, doi:10.1183/16000617.0076-2018.
    2. Cottin, V.; Wollin, L.; Fischer, A.; Quaresma, M.; Stowasser, S.; Harari, S. Fibrosing interstitial lung diseases: Knowns and unknowns. Eur. Respir. Rev. 2019, 28, 180100, doi:10.1183/16000617.0100-2018.
    3. Raghu, G.; Remy-Jardin, M.; Myers, J.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68, doi:10.1164/rccm.201807-1255st.
    4. Hutchinson, J.P.; Fogarty, A.W.; Hubbard, R.B.; McKeever, T.M. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review. Eur. Respir. J. 2015, 46, 795–806, doi:10.1183/09031936.00185114.
    5. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.-F.; Flaherty, K.R.; Lasky, J.A.; et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824, doi:10.1164/rccm.2009-040gl.
    6. Balestro, E.; Calabrese, F.; Turato, G.; Lunardi, F.; Bazzan, E.; Marulli, G.; Biondini, D.; Rossi, E.; Sanduzzi, A.; Rea, F.; et al. Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLoS ONE 2016, 11, e0154516, doi:10.1371/journal.pone.0154516.
    7. Kropski, J.A.; Blackwell, T.S. Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annu. Rev. Med. 2019, 70, 211–224.
    8. Martinez, F.J.; Collard, H.R.; Pardo, A.; Raghu, G.; Richeldi, L.; Selman, M.; Swigris, J.; Taniguchi, H.; Wells, A.U. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Prim. 2017, 3, 17074, doi:10.1038/nrdp.2017.74.
    9. Khor, Y.H.; Ng, Y.; Barnes, H.; Goh, N.S.; McDonald, C.F.; E Holland, A. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: A systematic review. Eur. Respir. Rev. 2020, 29, 190158, doi:10.1183/16000617.0158-2019.
    10. Lee, J.S.; Collard, H.R. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Pulm. Funct. Test. 2018, 194, 401–417, doi:10.1007/978-3-319-99975-3_17.
    11. Varga, J.; Marangoni, R.G. Systemic sclerosis in 2016: Dermal white adipose tissue implicated in SSc pathogenesis. Nat. Rev. Rheumatol. 2017, 13, 71–72.
    12. Mirsaeidi, M.; Barletta, P.; Glassberg, M.K. Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. Front. Med. 2019, 6, 248, doi:10.3389/fmed.2019.00248.
    13. Royle, J.G.; Lanyon, P.C.; Grainge, M.J.; Abhishek, A.; A Pearce, F. The incidence, prevalence, and survival of systemic scle-rosis in the UK Clinical Practice Research Datalink. Clin. Rheumatol. 2018, 37, 2103–2111, doi:10.1007/s10067-018-4182-3.
    14. Elhai, M.; Avouac, J.; Walker, U.A.; Cerinic, M.M.; Riemekasten, G.; Airó, P.; Hachulla, E.; Valentini, G.; E Carreira, P.; Cozzi, F.; et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study. Ann. Rheum. Dis. 2014, 75, 163–169, doi:10.1136/annrheumdis-2014-206386.
    15. Denton, C.P.; Khanna, D. Systemic sclerosis. Lancet 2017, 390, 1685–1699.
    16. Elhai, M.; Meune, C.; Boubaya, M.; Avouac, J.; Hachulla, E.; Balbir-Gurman, A.; Riemekasten, G.; Airã²P.; Joven, B.; Vettori, S.; et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 2017, 76, 1897–1905, doi:10.1136/annrheumdis-2017-211448.
    17. Distler, O.; Assassi, S.; Cottin, V.; Cutolo, M.; Danoff, S.K.; Denton, C.P.; Distler, J.H.; Hoffmann-Vold, A.-M.; Johnson, S.R.; Ladner, U.M.; et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur. Respir. J. 2020, 55, 1902026, doi:10.1183/13993003.02026-2019.
    18. Bernstein, E.J.; Jaafar, S.; Assassi, S.; Domsic, R.T.; Frech, T.M.; Gordon, J.K.; Broderick, R.J.; Hant, F.N.; Hinchcliff, M.E.; Shah, A.A.; et al. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2020, 72, 1892–1896, doi:10.1002/art.41415.
    19. Vacchi, C.; Sebastiani, M.; Cassone, G.; Cerri, S.; Della Casa, G.; Salvarani, C.; Manfredi, A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J. Clin. Med. 2020, 9, 407, doi:10.3390/jcm9020407.
    20. Walker, U.A.; Tyndall, A.; Czirjak, L.; Denton, C.; Farge-Bancel, D.; Kowal-Bielecka, O.; Muller-Ladner, U.; Bocelli-Tyndall, C.; Matucci-Cerinic, M. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scle-roderma Trials And Research group database. Ann. Rheum. Dis. 2007, 66, 754–763, doi:10.1136/ard.2006.062901.
    21. Bluett, J.; Jani, M.; Symmons, D.P.M. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Ar-thritis. Rheumatol. Ther. 2017, 4, 309–332, doi:10.1007/s40744-017-0071-5.
    22. Morisset, J.; Lee, J.S. New trajectories in the treatment of interstitial lung disease: Treat the disease or treat the underlying pattern? Curr. Opin. Pulm. Med. 2019, 25, 442–449.
    23. Raimundo, K.; Solomon, J.J.; Olson, A.L.; Kong, A.M.; Cole, A.L.; Fischer, A.; Swigris, J.J. Rheumatoid Arthritis–Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. J. Rheumatol. 2018, 46, 360–369, doi:10.3899/jrheum.171315.
    24. Wu, E.K.; Ambrosini, R.D.; Kottmann, R.M.; Ritchlin, C.T.; Schwarz, E.M.; Rahimi, H. Reinterpreting Evidence of Rheuma-toid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. Curr. Rheumatol. Rev. 2019, 15, 277–289, doi:10.2174/1573397115666190116102451.
    25. Esposito, A.J.; Chu, S.G.; Madan, R.; Doyle, T.J.; Dellaripa, P.F. Thoracic Manifestations of Rheumatoid Arthritis. Clin. Chest Med. 2019, 40, 545–560, doi:10.1016/j.ccm.2019.05.003.
    26. Sparks, J.A.; A Fletcher, E.; Huang, J.; Ba, E.A.F.; Bs, A.Z.; Ba, H.M.F.; Gill, R.R.; Hatabu, H.; Nishino, M.; Murphy, D.J.; et al. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis Rheumatol. 2019, 71, 1472–1482, doi:10.1002/art.40904.
    27. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012, 366, 1968–1977.
    28. Trang, G.; Steele, R.; Baron, M.; Hudson, M. Corticosteroids and the risk of scleroderma renal crisis: A systematic review. Rheumatol. Int. 2010, 32, 645–653, doi:10.1007/s00296-010-1697-6.
    29. Somogyi, V.; Chaudhuri, N.; Torrisi, S.E.; Kahn, N.; Müller, V.; Kreuter, M. The therapy of idiopathic pulmonary fibrosis: What is next? Eur. Respir. Rev. 2019, 28, 190021, doi:10.1183/16000617.0021-2019.
    30. Clement, D.; Ramage, J.; Srirajaskanthan, R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syn-drome. J. Oncol. 2020, 2020, 8341426–11, doi:10.1155/2020/8341426.
    31. Rothman, R.B.; Baumann, M.H.; Savage, J.E.; Rauser, L.; McBride, A.; Hufeisen, S.J.; Roth, B.L. Evidence for Possible In-volvement of 5-HT 2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medi-cations. Circ. 2000, 102, 2836–2841, doi:10.1161/01.cir.102.23.2836.
    32. Rothman, R.B.; Baumann, M.H. Serotonergic drugs and valvular heart disease. Expert. Opin. Drug Saf. 2009, 8, 317–329.
    33. Hutcheson, J.D.; Setola, V.; Roth, B.L.; Merryman, W.D. Serotonin receptors and heart valve disease—It was meant 2B. Pharmacol. Ther. 2011, 132, 146–157, doi:10.1016/j.pharmthera.2011.03.008.
    34. Löfdahl, A.; Rydell‐Törmänen, K.; Müller, C.; Holst, C.M.; Thiman, L.; Ekström, G.; Wenglén, C.; Larsson‐Callerfelt, A.; Westergren‐Thorsson, G. 5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic re-sponses in vitro and in vivo. Physiol. Rep. 2016, 4, e12873, doi:10.14814/phy2.12873.
    35. Elaidy, S.M.; Essawy, S.S. The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats. Pharmacol. Rep. 2016, 68, 1244–1253.
    36. Fabre, A.; Marchal-Sommé, J.; Marchand-Adam, S.; Quesnel, C.; Borie, R.; Dehoux, M.; Ruffie, C.; Callebert, J.; Launay, J.M.; Henin, D.; et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur. Respir. J. 2008, 32, 426–436, doi:10.1183/09031936.00126907.
    37. Tawfik, M.K.; Makary, S. 5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: Comparison to ter-guride. Eur. J. Pharmacol. 2017, 814, 114–123, doi:10.1016/j.ejphar.2017.08.014.
    38. Dees, C.; Akhmetshina, A.; Zerr, P.; Reich, N.; Palumbo, K.; Horn, A.; Jüngel, A.; Beyer, C.; Krönke, G.; Zwerina, J.; et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 2011, 208, 961–972, doi:10.1084/jem.20101629.
    39. Königshoff, M.; Dumitrascu, R.; Udalov, S.; Amarie, O.V.; Reiter, R.; Grimminger, F.; Seeger, W.; Schermuly, R.T.; Eickelberg, O. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: A rationale for therapeutic intervention. Thorax 2010, 65, 949–955, doi:10.1136/thx.2009.134353.
    40. Ebrahimkhani, M.R.; Oakley, F.; Murphy, L.B.; Mann, J.; Moles, A.; Perugorria, M.J.; Ellis, E.L.; Lakey, A.F.; Burt, A.D.; Douglass, A.; et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat. Med. 2011, 17, 1668–1673, doi:10.1038/nm.2490.
    More